Genomic disorders on chromosome 22

Current Opinion in Pediatrics

Volumn 24, Issue 6, 2012, Pages 665-671

  Yu, Shihui ^a,b   Graf, William D ^c   Shprintzen, Robert J ^d  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c YALE UNIVERSITY   (United States)

^d Virtual Center for Velo Cardio Facial Syndrome Inc   (United States)

Author keywords

catechol O methyltransferase; chromosome 22; copy number variants; outcome studies; velocardiofacial syndrome

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHYLPHENIDATE; S ADENOSYLMETHIONINE; SCATTER FACTOR RECEPTOR;

AGITATION; ATTENTION DEFICIT DISORDER; CHROMOSOME 22; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; CHROMOSOME TRANSLOCATION; COGNITIVE DEFECT; DEPRESSION; DOPAMINE METABOLISM; ESTROGEN METABOLISM; EXECUTIVE FUNCTION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MEMORY DISORDER; MONOSOMY; NEUROIMAGING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUALITY; TRANSLATIONAL RESEARCH; TRISOMY; VELOCARDIOFACIAL SYNDROME; WILLIAMS BEUREN SYNDROME;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; DIGEORGE SYNDROME; DNA COPY NUMBER VARIATIONS; GENOMICS; HUMANS; MICROARRAY ANALYSIS;

EID: 84870064641     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328358acd0     Document Type: Review

References (55)

1. Cole CG, McCanna OT, Collins JE, et al. Finishing the finished human chromosome 22 sequence. Genome Biol 2008; 9:R78.
2. Dunham I, Shimizu N, Roe BA, et al. The DNA sequence of human chromosome 22. Nature 1999; 402:489-495.
3. Robin NH, Shprintzen RJ. Defining the clinical spectrum of deletion 22q11.2. J Pediatr 2005; 147:90-96.
4. Yu S, Graf WD, Ramalingam A, et al. Identification of copy number variants on human chromosome 22 in patients with a variety of clinical findings. Cytogenet Genome Res 2011; 134:260-268.
5. Hassold T, Chen N, Funkhouser J, et al. A cytogenetic study of 1000 spontaneous abortions. Ann Hum Genet 1980; 44:151-178.
6. Ford JH, Wilkin HZ, Thomas P, McCarthy C. A 13-year cytogenetic study of spontaneous abortion: clinical applications of testing. Aust NZ J Obstet Gynaecol 1996; 36:314-318.
7. Warburton D, Byrne J, Canki N. Chromosome Anomalies and Prenatal Development: An Atlas. Oxford Monographs in Medical Genetics. Oxford, England: Oxford University Press; 1991.
8. Pflueger SMV. The Principles of Clinical Cytogenetics. In: Gersen SL, Keagle MB, editors. Cytogenetics of spontaneous abortion. Totowa, New Jersey: Humana Press; 1999. pp. 317-343.
9. Berends MJ, Tan-Sindhunata G, Leegte B, van Essen AJ. Phenotypic variability of Cat-Eye syndrome. Genet Couns 2001; 12:23-34.
10. Shprintzen RJ, Goldberg RB, Lewin ML, et al. A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardio-facial syndrome. Cleft Palate J 1978; 15:56-62.
11. Shprintzen RJ. Velo-cardio-facial syndrome:30 years of study. Dev Disabil Res Rev 2008; 14:3-10.
12. Gothelf D, Frisch A, Michaelovsky E, et al. Velo-Cardio-Facial Syndrome. J Ment Health Res Intellect Disabil 2009; 2:149-167.
13. Ensenauer RE, Adeyinka A, Flynn HC, et al. Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patients. Am J Hum Genet 2003; 73:1027-1040.
14. Ben-Shachar S, Ou Z, Shaw CA, et al. 22q11.2 distal deletion: a recurrent genomic disorder distinct from DiGeorge syndrome and velocardiofacial syndrome. Am J Hum Genet 2008; 82:214-221.
15. Coppinger J, McDonald-McGinn D, Zackai E, et al. Identification of familial and de novo microduplications of 22q11.21-q11.23 distal to the 22q11 21 microdeletion syndrome region. Hum Mol Genet 2009; 18:1377-1383.
16. McDermid HE, Morrow BE. Genomic disorders on 22q11. Am J Hum Genet 2002; 70:1077-1088.
17. Phelan MC. Deletion 22q13.3 syndrome. Orphanet J Rare Dis 2008; 3:14.
18. Shaikh TH, O'Connor RJ, Pierpont ME, et al. Low copy repeats mediate distal chromosome 22q11.2 deletions: sequence analysis predicts breakpoint mechanisms. Genome Res 2007; 17:482-491.
19. Mefford HC, Eichler EE. Duplication hotspots, rare genomic disorders, and common disease. Curr Opin Genet Dev 2009; 19:196-204.
20. Berg JS, Potocki L, Bacino CA. Common recurrent microduplication syndromes: diagnosis and management in clinical practice. Am J Med Genet A 2010; 152A:1066-1078.
21. Makoff AJ, Flomen RH. Detailed analysis of 15q11-q14 sequence corrects errors and gaps in the public access sequence to fully reveal large segmental duplications at breakpoints for Prader-Willi, Angelman, and inv dup(15) syndromes. Genome Biol 2007; 8:R114.
22. Lupski Jr. Structural variation in the human genome. N Engl J Med 2007; 356:1169-1171.
23. Gu W, Zhang F, Lupski Jr. Mechanisms for human genomic rearrangements. Pathogenetics 2008; 1:4.
24. Hastings PJ, Ira G, Lupski Jr. A microhomology-mediated break-induced replication model for the origin of human copy number variation. PLoS Genet 2009; 5:e1000327.
25. de Smith AJ, Walters RG, Coin LJ, et al. Small deletion variants have stable breakpoints commonly associated with alu elements. PLoS One 2008; 3:e3104.
26. Kidd JM, Graves T, Newman TL, et al. A human genome structural variation sequencing resource reveals insights into mutational mechanisms. Cell 2010; 143:837-847.
27. Conrad DF, Pinto D, Redon R, et al. Origins and functional impact of copy number variation in the human genome. Nature 2009; 464:704-712.
28. Mills RE, Walter K, Stewart C, Handsaker RE, et al. Mapping copy number variation by population-scalegenome sequencing.Nature 2011; 470:59-65.
29. Scambler PJ, Kelly D, Lindsay E, et al. Velo-cardio-facial syndrome associated with chromosome 22 deletions encompassing the DiGeorge locus. Lancet 1992; 339:1138-1139.
30. Driscoll DA, Spinner NB, Budarf ML, et al. Deletions and microdeletions of 22q11.2 in velo-cardio-facial syndrome. Am J Med Genet 1992; 44:261-268.
31. Golding-Kushner KJ, Weller G, Shprintzen RJ. Velo-cardio-facial syndrome: language and psychological profiles. J Craniofac Genet 1985; 5:259-266.
32. Shprintzen RJ, Goldberg R, Golding-Kushner KJ, Marion RW. Late-onset psychosis in the velo-cardio-facial syndrome. Am J Med Genet 1992; 42:141-142.
33. Carotti A, Marino B, Di Donato RM. Influence of chromosome 22q11.2 microdeletion on surgical outcome after treatment of tetralogy of Fallot with pulmonary atresia. J Thorac Cardiovasc Surg 2003; 126:1666-1667.
34. Versacci P, Michelon G, Carotti A, Marino B. Surgical results in patients with cardiac defects and Del 22q11.2 syndrome. Am J Cardiol 2011; 107:337-338.
35. Hirasaki S, Murakami K, Mizushima T, et al. Successful treatment of sepsis caused by staphylococcus lugdunensis in an adult with 22q11.2 deletion syndrome. Intern Med 2012; 51:377-380.
36. Brandão GR, de Souza Freitas JA, Flores Genaro K, et al. Speech outcomes and velopharyngeal function after surgical treatment of velopharyngeal insufficiency in individuals with signs of velocardiofacial syndrome. J Cranio-facial Surg 2011; 22:1736-1742.
37. Rottgers SA, Ford M, Cray J, et al. An algorithm for application of furlow palatoplasty to the treatment of velocardiofacial syndrome-associated velopharyngeal insufficiency. Ann Plast Surg 2011; 66:479-484.
38. Ysunza A, Pamplona MC, Santiago Morales MA. Velopharyngeal valving during speech, in patients with velocardiofacial syndrome and patients with nonsyndromic palatal clefts after surgical and speech pathology management. Int J Pediatr Otorhinolaryngol 2011; 75:1255-1259.
39. Spruijt NE, ReijmanHinze J, Hens G, et al. In search of the optimal surgical treatment for velopharyngeal dysfunction in 22q11.2 deletion syndrome: a systematic review. PLoS One 2012; 7:e34332.
40. Green T, Weinberger R, Diamond A, et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardio-facial syndrome. J Child Adolesc Psychopharmacol 2011; 21:589-595.
41. Green T, Steingart L, Frisch A, et al. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. J Neural Transm 2012. [Epub ahead of print]
42. Plaks M, Argaman R, Stawski M, et al. Social-sexual education in adolescents with behavioral neurogenetic syndromes. Isr J Psychiatry Relat Sci 2010; 47:118-124.
43. Stachon AC, de Souza C. Anxiety disorders and perceptual disturbances in adolescents with 22q11.2 deletion syndrome treated with SSRI: a case series. J Can Acad Child Adolesc Psychiatry 2011; 20:305-310.
44. Looman WS, Thurmes AK, O'Conner-Von SK. Quality of life among children with velocardiofacial syndrome. Cleft Palate Craniofac J 2010; 47:273-283.
45. Lachman HM, Morrow B, Shprintzen R, et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 1996; 67:468-472.
46. Graf WD, Unis AS, Yates C, et al. Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism. Neurology 2001; 57:410-416.
47. Antshel KM, Shprintzen RJ, Fremont W. Cognitive and psychiatric predictors to psychosis in velocardiofacial syndrome: a 3-year follow-up study. J Am Acad Child Adolesc Psychiatry 2010; 49:333-344.
48. Gothelf D, Feinstein C, Thompson T, et al. Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am J Psychiatry 2007; 164:663-669.
49. Coman IL, Gnirke MH, Middleton FA, et al. The effects of gender and Catechol O-Methyltransferase (COMT) Val158Met polymorphism on emotion regulation in velo-cardio-facial syndrome (22q11.2 Deletion Syndrome): a fMRI study. NeuroImage 2010; 53:1043-1050.
50. Van Amelsvoort T, Zinkstok T, Figee M, et al. Effects of a functional COMT polymorphism on brain anatomy and cognitive function in adults with velo-cardio-facial syndrome. Psychol Med 2008; 38:89-100.
51. Gothelf D, Hoeft F, Uenoc T, et al. Developmental changes in multivariate neuroanatomical patterns that predict risk for psychosis in 22q11.2 deletion syndrome. J Psychiatr Res 2011; 45:322-331.
52. Schneider M, van der Linden M, Glaser B, et al. Preliminary structure and predictive value of attenuated negative symptoms in 22q11.2 deletion syndrome. Psychiatry Res 2012; 196:277-284.
53. Salatino-Oliveira A, Genro JP, Guimarães AP, et al. Cathechol-Omethyltrans-ferase Val158Met polymorphism is associated with disruptive behavior disorders among children and adolescents with ADHD. J Neural Transm 2012; 119:729-733.
54. Serretti A, Olgiati PC. Catechol-o-methyltransferase and Alzheimer's disease: a review of biological and genetic findings. CNS Neurol Disord Drug Targets 2012; 11:299-305.
55. Oppenheimer A, Fulmer S, Shifteh K, et al. Cervical vascular and upper airway asymmetry in velo-cardio-facial syndrome: correlation of nasopharyngoscopy with MRA. Int J Pediatr Otorhinolaryngol 2010; 74:619-625.